Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy
– Financing accelerates development of lead candidate AV078, a CNS-penetrant selective mTORC1 inhibitor, and will fund completion of its Phase 2 clinical trial – Round co-led by Luma Group and CTI Life Sciences Fund, with…